NicOx SA : Ordinary Shareholder Meeting Of August 21, 2017

Published: Jul 31, 2017

Press Release
Ordinary Shareholder meeting of August 21, 2017

Conditions of availability of the preparatory documents

July 31, 2017 - release at 7:30 am CET
Sophia Antipolis, France

The shareholders of Nicox are convened to an ordinary shareholder meeting on first call on Monday August 21, 2017 at 2:00 pm CET in the offices of BuroClub - Drakkar 2 - building D - 2405 route des Dolines - 06560 Valbonne Sophia Antipolis - France.

The notice of convening containing the agenda and the draft resolutions was published in the BALO on July 17, 2017.

The documents mentioned in article R.225-83 of the French Code de commerce are made available to shareholders since the time of the notice of convening in accordance with applicable provisions:

all shareholders whose shares are in registered form may, up to the 5th day before the meeting (included) request that these documents be sent to them. For the shareholders whose shares are in bearer form, this right is subject to the provision of a share certificate to be issued by an authorized intermediary; and any shareholder can consult the documents at the headquarters of the Company during the 15 day period prior to the date of the meeting. Shareholders may vote by proxy or by attending the shareholder meeting in person. A guide explaining how to vote is available on Nicox's website. Shareholders may also contact the Company's Investor Relations team at for any question on the voting process.

In the event the quorum is not reached on the first call, Nicox will convene a shareholder meeting on second call on Monday September 4, 2017 at 2:00 pm CET in the offices of BuroClub - Drakkar 2 - building D - 2405 route des Dolines - 06560 Valbonne Sophia Antipolis - France.

About Nicox
Nicox is an international ophthalmic R&D company utilizing innovative science to maintain vision and improve ocular health. By leveraging its proprietary expertise in nitric oxide donation and other technologies, the Company is developing an extensive portfolio of novel therapies that target multiple ophthalmic conditions, including glaucoma. Nicox currently has an approved NDA product and another product at the pre-approval stage with the U.S. Food and Drug Administration (FDA) and a promising pipeline including next-generation stand-alone nitric-oxide donors, with the potential to treat a range of ophthalmic indications. Nicox is headquartered in Sophia Antipolis, France, is listed on Euronext Paris (Compartment B: Mid Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes.

For more information on Nicox, its products or pipeline, please visit: .
Analyst coverage
Bryan, Garnier & Co Hugo Solvet Paris, France
Invest Securities Martial Descoutures Paris, France
Gilbert Dupont Damien Choplain Paris, France

The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports.

Upcoming financial and business conferences

September 25-27 Cantor Fitzgerald's 3rd Annual Healthcare Conference New York; US
November 23-24 Actionaria 2017 Paris, France

Gavin Spencer,
Executive Vice President Corporate Development
T +33 (0)4 97 24 53 00
Investor Relations
United States
Argot Partners
Melissa Forst
T +1 (212) 600-1902
Media Relations
United Kingdom
Jonathan Birt
T +44 7860 361 746

Nicolas Merigeau
T +33 (0)1 44 71 94 98
United States
Argot Partners
Eliza Schleifstein
T +1 (917) 763-8106
The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.
Nicox S.A.
Drakkar 2
Bât D, 2405 route des Dolines
CS 10313, Sophia Antipolis
06560 Valbonne, France
T +33 (0)4 97 24 53 00
F +33 (0)4 97 24 53 99

Back to news